Floatz logo

CANDESARTAN

Migraine Without Aura

Norwegian University of Science and TechnologySmall moleculePhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Migraine Without Aura cohort.

Asset / SponsorPhaseRating
Topamax
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 4BBB
Dihydroergotamine mesylate
Satsuma Pharmaceuticals, Inc.
Phase 3BBB
PROPRANOLOL
Norwegian University of Science and Technology
Phase 3BB
Rimegepant
University of South Florida
Phase 4BB
METOCLOPRAMIDE
Assistance Publique - Hôpitaux de Paris
Phase 4BB

View all 50 →

Same molecule, other indications

CANDESARTAN is also rated in:

hypertensive disorderDormant
BB
Indicative ·
71 / 100
View asset →
stroke disorderDormant
BB
Indicative ·
68 / 100
View asset →
cardiovascular disorderDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →